{"id":"concerta-eg-formulation","safety":{"commonSideEffects":[{"rate":"10%","effect":"Insomnia"},{"rate":"10%","effect":"Headache"},{"rate":"5%","effect":"Nausea"},{"rate":"5%","effect":"Vomiting"},{"rate":"5%","effect":"Abdominal Pain"},{"rate":"5%","effect":"Dizziness"},{"rate":"5%","effect":"Fatigue"},{"rate":"5%","effect":"Anxiety"},{"rate":"5%","effect":"Irritability"},{"rate":"5%","effect":"Aggression"}]},"_chembl":{"chemblId":"CHEMBL3702600","moleculeType":"Small molecule","molecularWeight":"308.39"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Methylphenidate increases the levels of norepinephrine and dopamine in the brain by preventing their reuptake, which improves attention and impulse control.","oneSentence":"Methylphenidate acts as a norepinephrine-dopamine reuptake inhibitor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:08:48.240Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention Deficit Hyperactivity Disorder (ADHD)"}]},"trialDetails":[{"nctId":"NCT02730572","phase":"","title":"Concerta (Methylphenidate) -To-Generic Switch Study","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-09","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":1464}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Methylphenidate"],"phase":"phase_2","status":"active","brandName":"Concerta EG formulation","genericName":"Concerta EG formulation","companyName":"Janssen Research & Development, LLC","companyId":"johnson-johnson","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Concerta EG is a formulation of the small molecule methylphenidate, used to treat Attention Deficit Disorder With Hyperactivity. It is a generic version of Concerta, which is also available in an AG formulation.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2017-06-19T00:00:00.000Z","mah":"NEOS THERAPS INC","brand_name_local":"COTEMPLA XR-ODT","application_number":"NDA205489"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-06-19T00:00:00.000Z","mah":"ACTAVIS ELIZABETH","brand_name_local":"METHYLPHENIDATE","application_number":"ANDA210924"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-03-14T00:00:00.000Z","mah":"MYLAN TECH VIATRIS","brand_name_local":"METHYLPHENIDATE","application_number":"ANDA206497"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}